Showing results (1271-1280 of 2,447) with videos related to

Sort By:
Pageof 245
Annals of the Royal College of Surgeons of England|August 29, 2023
Oesophagopleural fistula after pneumonectomy: A systematic review and case seriesL Phelan, G R Layton, E H Lee, et al.
Assistive Technology : the Official Journal of RESNA|July 12, 2023
My assistive technology outcomes framework: Rights-based outcome tools for consumers to 'measure what matters'Natasha Layton, L Callaway, E Wilson, et al.
Chemosphere|May 22, 2003
Biodegradation of potential diesel oxygenate additives: dibutyl maleate (DBM), and tripropylene glycol methyl ether (TGME)Alfredo A Marchetti, Mark G Knize, Marina L Chiarappa-Zucca, et al.
Physiology & Behavior|August 10, 2019
Cardiac autonomic activity during sleep deprivation with and without caffeine administrationElena Crooks, Devon A Hansen, Brieann C Satterfield, et al.
Poultry Science|August 1, 2021
Evaluation of a subunit vaccine candidate (Biotech Vac Cox) against Eimeria spp. in broiler chickensEmanuel Gumina, Jeffrey W Hall, Bruno Vecchi, et al.
Drug Safety|January 26, 2008
Evaluation of risk profiles for gastrointestinal and cardiovascular adverse effects in nonselective NSAID and COX-2 inhibitor users: a cohort study using pharmacy dispensing data in The NetherlandsDeborah Layton, Patrick C Souverein, Eibert R Heerdink, et al.
International Journal of Molecular Medicine|December 19, 1998
Quantification of Ggamma- and Agamma-globins by electrospray ionisation mass spectrometryS F Ofori-Acquah, B N Green, B J Wild, et al.
Blood|October 15, 1996
Two novel mutations in the reduced nicotinamide adenine dinucleotide (NADH)-cytochrome b5 reductase gene of a patient with generalized type, hereditary methemoglobinemiaJ Manabe, R Arya, H Sumimoto, et al.
Clinical Endocrinology|February 16, 2018
Injection testosterone and adverse cardiovascular events: A case-crossover analysisJ Bradley Layton, Dongmei Li, Christoph R Meier, et al.
Pharmacoepidemiology and Drug Safety|September 30, 2008
Prescriber adoption of newly approved selective COX-2 inhibitorsDeborah Layton, Patrick C Souverein, Eibert R Heerdink, et al.
Pageof 245